FDA inspectors issued a report detailing quality control lapses at Novo Nordisk's main factory in North America as early as May last year.

Eli Lilly sued several compounding pharmacies, spas, and wellness centers for selling unapproved versions of Mounjaro.

"The idea here is you can still get a patent but it wouldn’t be implemented as a monopoly on a drug or vaccine or other medical technology."

A company that makes a crucial TB test has agreed to sell its product at cost for use in poor countries.

Chamber and government lawyers sparred over whether drugmakers have enough say in Medicare’s drug price-negotiation program.

A House committee took a first step toward legislation to fix hospital drug shortages, but do not expect a new law soon.

Ian Wilmut, the British scientist behind the first-ever cloning of a mammal, died Sept. 10, leaving behind a twofold legacy.

A HHS deal for a Regeneron drug marks the first time the administration has directly used its leverage to challenge list prices.

The leading decongestant used by millions of Americans is no better than a dummy pill, FDA scientiific advisers concluded.

Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial.

The FDA issued new guidelines clarifying the way they plan to evaluate medical devices that go through the controversial 510(k) pathway.

AstraZeneca appeared to play down speculation about CEO Pascal Soriot after a U.K. tabloid report that he was considering leaving.

President Biden’s nominee to lead NIH will get a hearing next month, perhaps thanks to a drug-pricing deal.

Novartis is changing the name — and the guiding strategy — of its research and development hub in Cambridge, Mass.

Oncologists in Philadelphia are alleging Jefferson Health system is violating federal antitrust and kickback laws by creating a “concerted campaign to eliminate” the group’s “presence in the oncology marketplace.”

“Maybe somebody is not yet ready for recovery, but that does not mean that they don’t deserve safety and peace and rest.”

Vaccine contracts show South Africa was “bullied” into one-sided deals with Covid-19 shot suppliers.

“If we're going to do it, let's make sure we're leveraging things that Amazon does really well, which is connecting buyers and sellers,” said Nworah Ayogu, Amazon Clinic’s chief medical…

Novartis is losing its chief commercial officer, Marie-France Tschudin, who has been seen as a rising star.

University of California students expected big pay hikes after an unprecedented strike, but they say it hasn't worked out that way.

Novartis sued in an attempt to halt Medicare drug-price negotiations, which include its top-selling heart-failure medicine Entresto.

J&J's Stelara was approved 98 days too early to qualify for an exemption from Medicare drug-price negotiations.

Layoffs in the U.S. pharmaceutical industry dipped in August, but the total for 2023 to date continues to outpace 2022.

On Tuesday, the U.S. government named 10 medicines that will be subject to Medicare price negotiations in 2026.

A new understanding of the butterfly effect has changed how one inpatient child psychologist approaches her patients.

Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say “Every new day should be unwrapped like a

Here's a look at winners and losers from Medicare’s newly released list of drugs subject to price negotiation.

The U.S. Federal Trade Commission suspended its challenge to Amgen's $27.8 billion acquisition of Horizon Therapeutics.

Good morning Pharmalittle students. This is Allison DeAngelis, filling in for Ed Silverman while he’s away from the Pharmalot campus. I debated assigning you a “What I did on my…

Good morning, Pharmalittle readers. Reporter Andrew Joseph here filling in for Ed from STAT’s London outpost, where we’re feeling a bit of panic having just looked at the calendar and…